NGNE · Neurogene Inc

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

535 W 24th Street, New York, NY, 10011, United States
Biotechnology
Healthcare

Market Cap

478.2M

52 Wk Range

$15.93 - $43.66

Previous Close

$23.10

Open

$22.97

Volume

247,168

Day Range

$22.28 - $23.74

Enterprise Value

130.6M

Cash

359.7M

Avg Qtr Burn

-29.15M

Insider Ownership

6.75%

Institutional Own.

N/A

Qtr Updated

Sep 30th 2026